ArticleMaterials today. Bio2025
VRK1 co-delivery mitigates DNA clustering by BAF in TFAMoplex transfection.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overcoming the nuclear barrier in nonviral gene therapy: mechanisms, carrier design, and translational perspectives on NLS peptide and DNA targeting sequence strategies.Drug delivery · 2026Review
- Barrier-to-Autointegration Factor 1: a key regulator of nuclear envelope integrity, genome stability, and disease progression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In non-viral gene delivery, DNA entering the cytoplasm is rapidly bound by barrier-to-autointegration factor (BAF) and surrounded by nuclear envelope-like membranes. This process is thought to mitigate the translocation of the DNA from the cytoplasm through the nuclear pores limiting the transfection of interphase cells. To prevent BAF clustering, we developed the protein-based gene delivery system TFAMoplex that uses the human mitochondrial transcription factor A (TFAM) which forms nanoparticles with DNA. In previous studies, we covalently fused the endogenous BAF inactivating enzyme vaccinia-related kinase 1 (VRK1) to TFAM, which, however, did not decrease BAF-mediated clustering of the transfected DNA. Here, we describe a modified TFAMoplex where VRK1 is linked to TFAM via a SpyTag/SpyCatcher linker system (SpyTFAMoplex). With this approach, quantitative image analysis, performed with transfected enhanced green fluorescent protein (EGFP)-BAF overexpressing HeLa cells, showed that cytoplasmic BAF clustering can be counteracted. A SpyTFAMoplex version comprising a kinase-inactive VRK1 mutant (dSpyTFAMoplex) exhibited twice the number of clusters per cell. The decrease in BAF clusters achieved with the active VRK1 system was accompanied by lower transfection efficiency in HeLa cells with significantly less (-72 %) mean fluorescence intensity of reporter gene expression compared to dSpyTFAMoplex. These data suggest that VRK1 in the SpyTFAMoplex interferes with BAF's DNA-binding ability, potentially impairing the mitotic nuclear entry pathway of exogenous DNA. While our study highlights the potential of co-delivering enzymes with DNA, further vector engineering is required to directly guide cytosolic DNA into the nucleus of interphase cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.